Sensus Healthcare (SRTS) Projected to Post Earnings on Wednesday

Sensus Healthcare (NASDAQ:SRTS) is expected to announce its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $8.3450 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 7:00 AM ET.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06. Sensus Healthcare had a negative return on equity of 5.67% and a negative net margin of 8.44%.The business had revenue of $6.88 million for the quarter, compared to analyst estimates of $6.31 million. On average, analysts expect Sensus Healthcare to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Sensus Healthcare Price Performance

Sensus Healthcare stock opened at $5.04 on Wednesday. The business has a 50 day moving average of $4.24 and a 200-day moving average of $3.90. The company has a market capitalization of $82.76 million, a P/E ratio of -26.53 and a beta of 1.21. Sensus Healthcare has a 1 year low of $3.03 and a 1 year high of $9.08.

Insiders Place Their Bets

In related news, Director Eric Sachetta acquired 7,000 shares of the firm’s stock in a transaction dated Friday, November 21st. The stock was purchased at an average cost of $3.93 per share, with a total value of $27,510.00. Following the completion of the acquisition, the director directly owned 140,113 shares of the company’s stock, valued at approximately $550,644.09. This trade represents a 5.26% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Joseph C. Sardano bought 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 18th. The shares were acquired at an average price of $4.03 per share, with a total value of $100,750.00. Following the completion of the transaction, the chief executive officer directly owned 1,200,293 shares of the company’s stock, valued at $4,837,180.79. This trade represents a 2.13% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders acquired 36,500 shares of company stock valued at $147,570. Corporate insiders own 8.90% of the company’s stock.

Institutional Investors Weigh In On Sensus Healthcare

An institutional investor recently raised its position in Sensus Healthcare stock. Geode Capital Management LLC lifted its stake in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) by 2.5% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 153,917 shares of the company’s stock after acquiring an additional 3,766 shares during the quarter. Geode Capital Management LLC owned approximately 0.94% of Sensus Healthcare worth $730,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 25.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on SRTS. Zacks Research raised Sensus Healthcare from a “strong sell” rating to a “hold” rating in a research note on Wednesday, October 22nd. Wall Street Zen upgraded shares of Sensus Healthcare from a “sell” rating to a “hold” rating in a report on Saturday, December 20th. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Sensus Healthcare in a research note on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $8.00.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.